Short Interest in Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Drops By 17.2%

Nautilus Biotechnology, Inc. (NASDAQ:NAUT) saw a large decline in short interest in January. As of January 15th, there was short interest totaling 368,545 shares, a decline of 17.2% from the December 31st total of 445,221 shares. Approximately 0.5% of the company’s shares are sold short. Based on an average trading volume of 234,616 shares, the days-to-cover ratio is presently 1.6 days. Based on an average trading volume of 234,616 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.5% of the company’s shares are sold short.

Institutional Investors Weigh In On Nautilus Biotechnology

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Callan Family Office LLC acquired a new position in Nautilus Biotechnology in the second quarter valued at $35,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Nautilus Biotechnology in the 3rd quarter valued at about $38,000. Qube Research & Technologies Ltd acquired a new position in Nautilus Biotechnology during the second quarter worth approximately $45,000. XTX Topco Ltd lifted its stake in Nautilus Biotechnology by 86.2% in the second quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock valued at $48,000 after buying an additional 30,641 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its holdings in shares of Nautilus Biotechnology by 468.3% in the first quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock valued at $51,000 after acquiring an additional 50,871 shares during the period. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Nautilus Biotechnology Stock Up 4.7%

Nautilus Biotechnology stock traded up $0.09 during midday trading on Monday, reaching $2.04. The company’s stock had a trading volume of 45,218 shares, compared to its average volume of 209,609. The company has a market cap of $257.80 million, a P/E ratio of -4.07 and a beta of 1.49. The business has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $1.36. Nautilus Biotechnology has a fifty-two week low of $0.62 and a fifty-two week high of $2.54.

Wall Street Analysts Forecast Growth

NAUT has been the subject of several recent research reports. Wall Street Zen raised shares of Nautilus Biotechnology from a “sell” rating to a “hold” rating in a research note on Tuesday, November 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell” and an average target price of $2.50.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.